Risk Of Chronic Heart Failure With Insulin Sensitizers

More patients were diagnosed with chronic heart failure after 6 months of starting rosiglitazone. A group of researchers led by Dr Jennifer Marceille of the Edward Hines Jr. Veterans Affairs Medical Center in Hines, USA, evaluated the relationship between rosiglitazone therapy and chronic heart failure in patients with type 2 diabetes. A total of 139 patients were identified who were receiving insulin therapy and had rosiglitazone added to their therapy. Medical records were reviewed for 6 months before and 6 months after initiation of rosiglitazone treatment.

The researchers found that chronic heart failure was diagnosed in 25% of patients before starting rosiglitazone and in 30% after starting rosiglitazone. Medical intervention for chronic heart failure was needed in 36% of patients after starting rosiglitazone, compared with 14% before rosiglitazone (p<0.0001). Of the patients requiring medical intervention after starting rosiglitazone, 66% had not needed any intervention before starting rosiglitazone. The most common symptom was lower-extremity oedema, which occurred in 18% of patients before starting rosiglitazone and in 36% after starting rosiglitazone (p<0.0001).

The researchers concluded that more patients were diagnosed with chronic heart failure during the 6 months after starting rosiglitazone than in the 6 months before starting rosiglitazone in insulin-treated patients with type 2 diabetes.

Pharmacotherapy 2004;24:1317-22

=============================

WarmFeet Kit can help with painful neuropathy and wound healing.

To Find our more:

https://www.diabetesincontrol.com/modules.php?name=News&file=article&sid=2007

The 10,000 STEP STUDY:

"The Results". A simple answer to a difficult problem.

https://www.diabetesincontrol.com/modules.php?name=News&file=article&sid=2001